title: Magnetic resonance imaging of tumor oxygenation and metabolic profile.
abstract: The tumor microenvironment is distinct from normal tissue as a result of abnormal vascular network characterized by hypoxia, low pH, high interstitial fluid pressure and elevated glycolytic activity. This poses a barrier to treatments including radiation therapy and chemotherapy. Imaging methods which can characterize such features non-invasively and repeatedly will be of significant value in planning treatment as well as monitoring response to treatment. The three techniques based on magnetic resonance imaging (MRI) are reviewed here. Tumor pO2 can be measured by two MRI methods requiring an exogenous contrast agent: electron paramagnetic resonance imaging (EPRI) and Overhauser magnetic resonance imaging (OMRI). Tumor metabolic profile can be assessed by a third method, hyperpolarized metabolic MR, based on injection of hyperpolarized biological molecules labeled with (13)C or (15)N and MR spectroscopic imaging. Imaging pO2 in tumors is now a robust pre-clinical imaging modality with potential for implementation clinically. Pre-clinical studies and an initial clinical study with hyperpolarized metabolic MR have been successful and suggest that the method may be part of image-guided radiotherapy to select patients for tailored individual treatment regimens.
authors: Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, NIH , Bethesda, Maryland , USA.
authors: Murali C
authors: MC
authors: Krishna
authors: Shingo
authors: S
authors: Matsumoto
authors: Keita
authors: K
authors: Saito
authors: Masayuki
authors: M
authors: Matsuo
authors: James B
authors: JB
authors: Mitchell
authors: Jan H
authors: JH
authors: Ardenkjaer-Larsen
mesh_terms: D000818:Animals; D006801:Humans; D008279:Magnetic Resonance Imaging; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism*; D010100:Oxygen / Q000378:metabolism*
chemical_list: D010100:Oxygen
references: Nat Rev Cancer. 2006 Aug;6(8):583-92
references: 16862189
references: Nat Med. 2007 Nov;13(11):1382-7
references: 17965722
references: Radiother Oncol. 1998 Feb;46(2):135-46
references: 9510041
references: Acta Oncol. 2008;47(7):1182-5
references: 18654901
references: Cancer Res. 2010 Dec 15;70(24):10019-23
references: 21159626
references: Radiother Oncol. 2011 Jul;100(1):22-32
references: 21511351
references: Semin Radiat Oncol. 1996 Jan;6(1):10-21
references: 10717158
references: Nat Rev Cancer. 2004 Jun;4(6):437-47
references: 15170446
references: Nat Rev Clin Oncol. 2012 Dec;9(12):674-87
references: 23149893
references: Acta Oncol. 2010 Oct;49(7):884-7
references: 20831476
references: Cancer Metastasis Rev. 2007 Jun;26(2):225-39
references: 17440684
references: J Magn Reson. 1998 Jul;133(1):1-12
references: 9654463
references: Int J Radiat Biol. 2006 Oct;82(10):699-757
references: 17118889
references: Magn Reson Med. 2013 May;69(5):1443-50
references: 22692861
references: Cancer Res. 1987 Jan 15;47(2):597-601
references: 3791244
references: Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10158-63
references: 12930897
references: Cancer Res. 1999 Dec 1;59(23):5863-70
references: 10606224
references: Q J Nucl Med. 2001 Jun;45(2):183-8
references: 11476169
references: Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19801-6
references: 19903889
references: J Bioenerg Biomembr. 2007 Jun;39(3):251-7
references: 17624581
references: J Clin Invest. 2008 May;118(5):1965-73
references: 18431513
references: Br J Cancer. 1955 Dec;9(4):539-49
references: 13304213
references: Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10435-9
references: 12930896
references: Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2216-21
references: 11854518
references: Cancer Res. 2008 Oct 15;68(20):8607-15
references: 18922937